Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Tsinghua University, Beijing, China.
Nature. 2019 Mar;567(7749):525-529. doi: 10.1038/s41586-019-0979-8. Epub 2019 Feb 27.
T cells become dysfunctional when they encounter self antigens or are exposed to chronic infection or to the tumour microenvironment. The function of T cells is tightly regulated by a combinational co-stimulatory signal, and dominance of negative co-stimulation results in T cell dysfunction. However, the molecular mechanisms that underlie this dysfunction remain unclear. Here, using an in vitro T cell tolerance induction system in mice, we characterize genome-wide epigenetic and gene expression features in tolerant T cells, and show that they are distinct from effector and regulatory T cells. Notably, the transcription factor NR4A1 is stably expressed at high levels in tolerant T cells. Overexpression of NR4A1 inhibits effector T cell differentiation, whereas deletion of NR4A1 overcomes T cell tolerance and exaggerates effector function, as well as enhancing immunity against tumour and chronic virus. Mechanistically, NR4A1 is preferentially recruited to binding sites of the transcription factor AP-1, where it represses effector-gene expression by inhibiting AP-1 function. NR4A1 binding also promotes acetylation of histone 3 at lysine 27 (H3K27ac), leading to activation of tolerance-related genes. This study thus identifies NR4A1 as a key general regulator in the induction of T cell dysfunction, and a potential target for tumour immunotherapy.
当 T 细胞遇到自身抗原或暴露于慢性感染或肿瘤微环境时,它们会变得功能失调。T 细胞的功能受到组合性共刺激信号的严格调节,而负共刺激的优势会导致 T 细胞功能失调。然而,导致这种功能失调的分子机制尚不清楚。在这里,我们使用小鼠体外 T 细胞耐受诱导系统,对耐受 T 细胞中的全基因组表观遗传和基因表达特征进行了表征,并表明它们与效应 T 细胞和调节性 T 细胞不同。值得注意的是,转录因子 NR4A1 在耐受 T 细胞中稳定地高表达。NR4A1 的过表达抑制效应 T 细胞分化,而 NR4A1 的缺失则克服了 T 细胞耐受并夸大了效应功能,同时增强了对肿瘤和慢性病毒的免疫。在机制上,NR4A1 优先被募集到转录因子 AP-1 的结合位点,在那里通过抑制 AP-1 功能来抑制效应基因的表达。NR4A1 结合还促进组蛋白 3 赖氨酸 27(H3K27ac)的乙酰化,从而激活与耐受相关的基因。因此,这项研究确定 NR4A1 是诱导 T 细胞功能失调的关键通用调节剂,也是肿瘤免疫治疗的潜在靶点。